Peptide Stacking for Lifters: Synergy, Overlap and Evidence

What stacking means on this page

Stacking means running two or more peptides at the same time, usually on the idea that the right pair does more than either one alone. Forum guides call this synergy. For one pairing, a GHRH analog with a GHRP, human lab studies do show a larger growth hormone (GH) response than either compound gives by itself. For most other popular stacks, the case rests on mechanism arguments and user reports.

For how stacks fit into on/off schedules, see our overview of peptide cycling protocols for bodybuilders. Every dose below is labeled by its source. None is a recommendation.

GHRH plus GHRP: the pairing with human data

The pituitary's GH release is controlled by two stimulating signals and one brake. GHRH acts on its own receptor. Ghrelin and the synthetic GHRPs act on the ghrelin receptor (GHS-R1a). Somatostatin holds both back. CJC-1295 and Mod GRF 1-29 are GHRH analogs, and ipamorelin is the GHRP most users pair with them.

Because the two signals use different receptors, giving both at once releases more GH than either alone. In a 2009 Mayo Clinic study, researchers infused GHRH and GHRP-2 together into 47 healthy men aged 18-74. The combined response was large but uneven. Synergy was weaker in older men and in men with more abdominal visceral fat, and stronger in men with higher IGF-1.

Those were IV infusions measuring hormone levels over hours, not months of subcutaneous use. As of October 2026, no controlled human trial has tested Mod GRF 1-29 plus ipamorelin, or any GHRH-GHRP stack, for body composition or strength. Ipamorelin's only efficacy trial was an IV study after abdominal surgery (56 patients on ipamorelin, 58 on placebo). It missed its primary endpoint, and development stopped. Our peptide comparison page covers what each compound has and hasn't shown.

Two rules stacking guides repeat

Combine different pathways, not the same receptor

The standard advice is one GHRH analog plus one GHRP, not two GHRPs. Ipamorelin and GHRP-2 both act on the ghrelin receptor; a 1998 study from Novo Nordisk, which developed ipamorelin, confirmed that it works through the same receptor as GHRP-6. A second drug aimed at an already-stimulated receptor probably adds little GH, though nobody has tested ipamorelin plus GHRP-2 in people.

There's also a side-effect cost. In the pigs in that same study, GHRP-2 and GHRP-6 raised ACTH and cortisol. Ipamorelin didn't, even at doses more than 200 times what it took to release GH. Adding GHRP-2 on top of ipamorelin brings back the effect that made ipamorelin the popular choice. Users also report intense hunger with GHRP-6, which isn't among the side effects commonly reported for ipamorelin.

Build around one goal

Guides also suggest picking one main goal, such as injury recovery or a cut, and choosing compounds for it. Adding a recovery peptide to a mass stack is common because heavy training loads connective tissue. Adding a fat-loss compound to a mass stack is rarer and makes the protocol harder to interpret.

Short stacks also make side effects easier to trace: with four compounds running, there's no way to tell which one caused flushing or numb hands. Each extra vial is another product of uncertain identity, too.

Common stacks and what supports them

These three templates come up repeatedly in forums and vendor guides.

Mass stack: CJC-1295 with DAC plus ipamorelin

The idea is a long-acting GHRH analog to raise GH across the week, with ipamorelin layered on for sharper pulses. Many guides, including an earlier version of this page, say CJC-1295 with DAC causes a constant GH "bleed" that flattens natural pulses. The human data say otherwise. In a 2006 study, Ionescu and Frohman sampled GH every 20 minutes overnight in healthy men aged 20-40, before and one week after a single 60 or 90 mcg/kg injection. Pulse frequency and size didn't change. The trough between pulses rose 7.5-fold, lifting mean GH by 46% and IGF-1 by 45%. The DAC version raises the floor under the pulses; it doesn't replace them.

Dose-ranging trials published the same year (Teichman and colleagues) found a half-life of 5.8-8.1 days, with GH raised for 6 days or more after one injection. Doses of 30-60 mcg/kg were the best tolerated. FDA's compounding safety page lists increased heart rate and a systemic vasodilatory reaction among serious adverse events associated with CJC-1295. Users commonly report flushing and water retention.

Some lifters add BPC-157 to protect connective tissue. That preventive use has no human data behind it (see the recovery stack below).

Cutting stack: Mod GRF 1-29 plus ipamorelin, sometimes with HGH fragment 176-191

Mod GRF 1-29 (CJC-1295 without DAC) is short-acting, so it produces a brief pulse instead of a week of raised trough levels. Forum users commonly describe 100-300 mcg each of Mod GRF and ipamorelin at bedtime, often five days on and two off. Lifters prefer it for cutting because they report less water retention than with the DAC version. Nobody has compared the two directly.

HGH fragment 176-191 gets added for fat loss, often injected before fasted cardio. The closest human data come from AOD-9604, a modified version of the same fragment. In its largest trial (OPTIONS, 502 adults with obesity), oral doses of 0.25-1 mg daily for 24 weeks didn't beat placebo for weight loss, according to FDA's 2024 briefing. No human trial has tested an injected version, so the fasted-cardio timing is community practice.

Recovery stack: BPC-157 plus TB-500

This is the most popular recovery combination, often sold as the "Wolverine" stack, and its reputation is well ahead of its evidence. A 2025 systematic review of BPC-157 in orthopaedic sports medicine included 36 studies; 35 were preclinical. Only three small pilot studies have given BPC-157 to people, and none had a control group. The site rates its evidence as emerging.

The case for TB-500 is thinner. Anti-doping chemists identified it as a seven-amino-acid fragment (Ac-LKKTETQ) of thymosin beta-4, a 43-amino-acid protein. Human trials of thymosin beta-4 used the full protein, and FDA says it has found no human exposure data for the fragment. The site rates TB-500 as preliminary.

The usual explanation for the pairing is that BPC-157 works locally by promoting angiogenesis at the injury while TB-500 works systemically on cell migration. That split is a community model. Rodent BPC-157 studies have used systemic routes such as intraperitoneal and oral dosing, and most of the cell-migration work on thymosin beta-4 used the full protein. For the combination itself, the only human report is a 2021 uncontrolled chart review of 16 knee-pain patients, some of whom received BPC-157 with thymosin beta-4; 14 reported relief. One vendor's review of pre-mixed blends such as KLOW (checked September 2026) found no study of any blend in people or animals.

Users commonly report 250-500 mcg of BPC-157 per day. For TB-500, vendor guidance describes 2-2.5 mg twice weekly for 4-6 weeks, then monthly maintenance doses, while forum users describe 2-5 mg twice weekly. No human dose has been tested for the TB-500 fragment. Some users also add nightly ipamorelin, reasoning that higher IGF-1 helps tissue repair; no study has tested that.

Timing claims

Most stacking guides say GH-releasing peptides belong on an empty stomach, because food, especially carbohydrate, is said to blunt the GH response. We found no study testing meal timing with ipamorelin or Mod GRF 1-29, so the two-hour fasting window guides repeat is community practice.

Bedtime dosing has better physiology behind it. Research on GH and sleep shows that in healthy young men, a pulse around sleep onset is often the main or only GH burst of the day, and its size tracks the amount of slow-wave sleep. Nobody has tested whether timing a dose to that pulse changes results.

Regulatory status

As of October 2026, WADA's 2026 Prohibited List bans every peptide on this page at all times. BPC-157 falls under S0 (non-approved substances). GHRH analogs such as CJC-1295 and Mod GRF 1-29 sit under S2.2.4 with the GHRPs, including ipamorelin. AOD-9604 and hGH 176-191 are named under S2.2.3, and TB-500 under S2.3.

None of these is an FDA-approved drug. FDA's compounding safety-risk page (current as of April 22, 2026) lists BPC-157, TB-500, CJC-1295 and AOD-9604 as nominated-but-withdrawn substances and keeps ipamorelin in Category 2 for outsourcing facilities. Our page on peptide ethics for lifters covers what this means in tested and untested sport.

What we still don't know

• Whether any stack beats its parts on body composition or recovery in people. The GHRH-GHRP synergy data measure hormones, not outcomes.
• What months of raised trough GH from CJC-1295 with DAC do to blood sugar and IGF-1. Our page on long-term effects of peptide cycling covers the closest human data.
• Whether BPC-157 and TB-500 together do more than either alone. Nobody has tested the pair in a controlled study.
• What a given vial or blend actually contains, since research-use vials aren't regulated as drugs.